Zura Bio Public Offering Raises $144 Million in Gross Proceeds
The Zura Bio public offering has officially closed, raising approximately $144 million in gross proceeds to support the company’s clinical development strategy. Zura Bio Limited, a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases, completed the underwritten transaction on February 26, 2026.
The offering consisted of 21.2 million Class A ordinary shares priced at $6.25 per share. In addition, 1.8 million pre-funded warrants were issued at $6.249 each. Importantly, the underwriters exercised their option in full to purchase an additional 3 million shares. As a result, the total capital raised reached roughly $144 million before underwriting discounts and other related expenses.
Capital to Accelerate Clinical Programs
The Zura Bio public offering strengthens the company’s balance sheet and extends its financial runway. Consequently, the company can accelerate research, expand clinical trials, and support the advancement of its differentiated autoimmune pipeline.
Biotechnology companies require substantial funding to navigate regulatory pathways and late-stage studies. Therefore, this successful raise provides both stability and strategic flexibility. Moreover, strong institutional participation signals confidence in the company’s long-term growth potential.
The securities were issued under a shelf registration statement filed with the U.S. Securities and Exchange Commission and declared effective in September 2024. Leerink Partners, Piper Sandler, and Cantor acted as joint bookrunning managers for the transaction, while Wedbush PacGrow served as lead manager.
Positioning for Long-Term Growth
With additional capital secured, Zura is well positioned to execute its development roadmap. As competition in autoimmune therapeutics intensifies, adequate funding remains critical. Ultimately, this financing milestone supports continued innovation while advancing treatments aimed at improving patient outcomes worldwide.
Read Also: Niagen Bioscience Sells ChromaDex Reference Standards Business to LGC in All-Cash Deal
